Advertisement

Der Nervenarzt

, Volume 78, Issue 1, pp 7–14 | Cite as

Antidepressiva und Suizidalität

Nutzen-Risiko-Abschätzung
  • U. HegerlEmail author
Übersichten

Zusammenfassung

Bei Kindern und Jugendlichen haben Reanalysen plazebokontrollierter Studien Hinweise auf ein erhöhtes Risiko suizidaler Gedanken und suizidaler sowie feindseliger Handlungen nach Behandlung mit SSRI oder anderen neueren Antidepressiva gefunden. Auch wenn es zu keinem Suizid kam, so gewinnen diese Befunde an Gewicht, da mit Ausnahme von Fluoxetin die Evidenzlage bezüglich der antidepressiven Wirksamkeit in dieser Altersgruppe schwach oder fehlend ist. Bei Erwachsenen gibt es keinen Grund, an der suizidpräventiven Wirkung der Antidepressiva zu zweifeln. Ein ausgeprägter suizidinduzierender Effekt der SSRI oder anderer neuerer Antidepressiva kann weitgehend ausgeschlossen werden. Andererseits kann bei vulnerablen Patienten gerade zu Beginn einer Medikation mit Antidepressiva das Suizidrisiko ansteigen. Es gibt keine Belege, dass dieses Risiko für SSRI höher als für andere Antidepressiva oder nichtpharmakologische Behandlungen ist. Die Überdosierungssicherheit ist ein starkes Argument bei ambulanten Patienten mit unklarer Suizidalität, neuere Antidepressiva den trizyklischen Antidepressiva vorzuziehen.

Schlüsselwörter

Depression Suizid Antidepressiva Selektive Serotoninwiederaufnahmehemmer 

Antidepressants and suicidality

Risk-benefit analysis

Summary

Reanalyses of placebo-controlled trials reveal an increased risk of suicidal ideations or parasuicidal acts in children and adolescents under treatment with selective serotonin reuptake inhibitors (SSRI) or other antidepressants. Although no completed suicide was shown, these findings are the more important because, with the exception of fluoxetine, an evidence base for the efficacy of antidepressants is weak or lacking in this age group. For adults, there is no reason to doubt that antidepressants help to reduce suicides by shortening depressive episodes and preventing recurrence. A general and pronounced suicide-inducing effect of SSRI or other antidepressants can largely be excluded. On the other hand, in some vulnerable patients the risk of suicidal acts can increase, especially during the first days of antidepressant treatment. There is no evidence that this risk is higher with SSRI than with other antidepressants or nonpharmacological treatments. Safety in case of overdose is a strong argument favouring newer antidepressants over tri- and tetracyclic antidepressants in outpatients with unclear suicidality. The current widespread public discussions concering the risks of antidepressants is a risk in itself because confidence in treatment, compliance, and help seeking behaviour may get influenced negatively.

Keywords

Depression Suicide Antidepressants Selective serotonin reuptake inhibitors 

Literatur

  1. 1.
    Ansorge MS, Zhou M, Lira A et al. (2004) Early-life blockade of the 5-HT transporter alters emotional behaviour in adult mice. Science 306:879–881CrossRefPubMedGoogle Scholar
  2. 2.
    Barbui C, Campomori A, D’Avanzo B et al. (1999) Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates. Soc Psychiatry Psychiatr Epidemiol 34:152–156CrossRefPubMedGoogle Scholar
  3. 3.
    Bridge JA, Salary CB, Birmaher B et al. (2005) The risks and benefits of antidepressant treatment for youth depression. Ann Med 37:404–412CrossRefPubMedGoogle Scholar
  4. 4.
    Emslie GJ, Heiligenstein JH, Hoog SL et al. (2004) Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 43:1397–1405CrossRefPubMedGoogle Scholar
  5. 5.
    Fegert JM, Herpertz-Dahlmann B (2005) Serotoninwiederaufnahmehemmer im Kindes- und Jugendalter. Nervenarzt 76:1330–1339CrossRefPubMedGoogle Scholar
  6. 6.
    Fergusson D, Doucette S, Glass K et al. (2005) Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 330:396–402CrossRefPubMedGoogle Scholar
  7. 7.
    Freemantle N, House A, Song F et al. (1994) Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. BMJ 309:249–253PubMedGoogle Scholar
  8. 8.
    Frey R, Schreinzer D, Stimpfl T et al. (2000) Suicide by antidepressant intoxication identified at autopsy in Vienna from 1991–1997: the favourable consequences oft he increasing use of SSRIs. Eur Neuropsychopharmacol 10:133–142CrossRefPubMedGoogle Scholar
  9. 9.
    Frey R, Schreinzer D, Stimpfl T et al. (2002) Letale Intoxikationen mit Antidepressiva und Neuroleptika. Analyse im Zusammenhang mit den Verordnungen in Wien von 1991 bis 1997. Nervenarzt 73:629–636CrossRefPubMedGoogle Scholar
  10. 10.
    Gibbons RD, Hur K, Bhaumik DK et al. (2005) The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 62:165–172CrossRefPubMedGoogle Scholar
  11. 11.
    Gunnell D, Ashby D (2004) Antidepressants and suicide: what is the balance of benefit and harm. BMJ 329:34–38CrossRefPubMedGoogle Scholar
  12. 12.
    Gunnell D, Ho D, Murray V (2004) Medical management of deliberate drug overdose: a neglected area for suicide prevention? Emerg Med J 21:35–38CrossRefPubMedGoogle Scholar
  13. 13.
    Gunnell D, Saperia J, Ashby D (2005) Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 330:385–389CrossRefPubMedGoogle Scholar
  14. 14.
    Hall WD, Mant A, Mitchell PB et al. (2003) Association between antidepressant prescribing and suicide in Australia, 1991–2000: trend analysis. BMJ 326:1008–1011CrossRefPubMedGoogle Scholar
  15. 15.
    Healy D (2003) Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 72:71–79CrossRefPubMedGoogle Scholar
  16. 16.
    Healy D, Langmaak C, Savage M (1999) Suicide in the course of the treatment of depression. J Psychopharmacol 13:94–99PubMedGoogle Scholar
  17. 17.
    Helgason T, Tómasson H, Zoega T (2004) Antidepressants and public health in Iceland. Time series analysis of national data. Br J Psychiatry 184:157–162CrossRefPubMedGoogle Scholar
  18. 18.
    Isacsson G (2000) Suicide prevention—a medical breakthrough? Acta Psychiatr Scand 102:113–117CrossRefPubMedGoogle Scholar
  19. 19.
    Isacsson G, Holmgren P, Ahlner J (2005) Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14.857 suicides. Acta Psychiatr Scand 111:286–290CrossRefPubMedGoogle Scholar
  20. 20.
    Jick H, Kaye JA, Jick SS (2004) Antidepressants and the risk of suicidal behaviors. JAMA 292:338–343CrossRefPubMedGoogle Scholar
  21. 21.
    Kelly CB, Ansari T, Rafferty T et al. (2003) Antidepressant prescribing and suicide rate in Northern Ireland. Eur Psychiatry 18:325–328CrossRefPubMedGoogle Scholar
  22. 22.
    Khan A, Khan S, Kolts R et al. (2003) Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 160:790–792Google Scholar
  23. 23.
    Lohse M, Lorenzen A, Müller-Oerlinghausen B (2004) Psychopharmaka. In: Schwabe U, Paffrath D (Hrsg) Arzneiverordnungsreport 2004. Springer, Berlin Heidelberg New York, S 769–810Google Scholar
  24. 24.
    Lönnqvist J (2000) Psychiatric aspects of suicidal behaviour: depression. In: Hawton K, van Heeringen K (eds) The international handbook of suicide and attempted suicide. Wiley, Chichester, pp 107–120Google Scholar
  25. 25.
    March J, Silva S, Petrycki S et al. (2004) Fluoxetine, cognitive-behavioural therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 292:807–820CrossRefPubMedGoogle Scholar
  26. 26.
    Martinez C, Rietbrock S, Wise L et al. (2005) Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 330:389–395CrossRefPubMedGoogle Scholar
  27. 27.
    Möller HJ (1994) Einfluss von Antidepressiva auf die Suizidalität depressiver Patienten. Fortschr Neurol Psychiatr 62(Sonderheft 1):19–23Google Scholar
  28. 28.
    Müller-Oerlinghausen B, Berghöfer A (1999) Antidepressants and suicidal risk. J Clin Psychiatry 60(Suppl 2):94–99Google Scholar
  29. 29.
    Olfson M, Marcus SC, Weissman MM et al. (2003) National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 41:514–521Google Scholar
  30. 30.
    Simon GE, Savarino J, Operskalski B et al. (2006) Suicide risk during antidepressant treatment. Am J Psychiatry 163:41–47CrossRefPubMedGoogle Scholar
  31. 31.
    US Food and Drug Administration (2004) FDA statement on recommendations of the Psychopharmacologic Drugs and Paediatric Advisory Committees. http://www.fda.gov/bbs/topics/news/2004/ NEW01116.html.
  32. 32.
    Valuck RJ, Libby AM, Sills MR et al. (2004) Antidepressant treatment and risk of suicide attempt by adolescents with major depressive disorder: a propensity-adjusted retrospective cohort study. CNS Drugs 18:1119–1132CrossRefPubMedGoogle Scholar
  33. 33.
    Vitiello B, Swedo S (2004) Antidepressant medications in children. N Engl J Med 350:1489–1491CrossRefPubMedGoogle Scholar
  34. 34.
    Whittington CJ, Kendall T, Fonagy P et al. (2004) Selective serotonin reuptake inhibitors in childhood depression: a systematic review of published versus unpublished data. Lancet 363:1341–1345CrossRefPubMedGoogle Scholar
  35. 35.
    Whyte IM, Dawson AH, Buckley NA (2003) Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. Q J Med 96:369–374Google Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  1. 1.Abteilung für Klinische NeurophysiologiePsychiatrische Klinik der Ludwig-Maximilians-UniversitätMünchen

Personalised recommendations